A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
Public ClinicalTrials.gov record NCT04173065. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This visit represents the End-of-Study Visit (Week 56 Visit). Three hundred thirty-seven subjects will be enrolled into five treatment arms and there will be an equal distribution of males and females in each treatment arm. Subjects will be stratified by gender, fibrosis stage, and diabetes status.
Study identification
- NCT ID
- NCT04173065
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 248 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2019
- Primary completion
- May 14, 2023
- Completion
- Jan 25, 2024
- Last update posted
- Jun 13, 2024
2019 – 2024
United States locations
- U.S. sites
- 68
- U.S. states
- 27
- U.S. cities
- 60
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Viking Clinical Site 105 | Madison | Alabama | 35758 | — |
| Viking Clinical Site 216 | Glendale | Arizona | 85306 | — |
| Viking Clinical Site 159 | Tucson | Arizona | 85712 | — |
| Viking Clinical Site 214 | North Little Rock | Arkansas | 72117 | — |
| Viking Clinical Site 161 | Fresno | California | 93701 | — |
| Viking Clinical Site 208 | Fresno | California | 93720 | — |
| Viking Clinical Site 302 | La Jolla | California | 92037 | — |
| Viking Clinical Site 134 | Montclair | California | 91736 | — |
| Viking Clinical Site 205 | Panorama City | California | 91402 | — |
| Viking Clinical Site 125 | Pasadena | California | 91105 | — |
| Viking Clinical Site 110 | Rialto | California | 92377 | — |
| Viking Clinical Site 117 | Sacramento | California | 95817 | — |
| Viking Clinical Site 121 | San Diego | California | 92037 | — |
| Viking Clinical Site 103 | San Francisco | California | 94115 | — |
| Viking Clinical Site 156 | New Haven | Connecticut | 06510 | — |
| Viking Clinical Site 226 | Bradenton | Florida | 34208 | — |
| Viking Clinical Site 150 | Lakewood Rch | Florida | 34211 | — |
| Viking Clinical Site 106 | Miami | Florida | 33014 | — |
| Viking Clinical Site 301 | Miami | Florida | 33136 | — |
| Viking Clinical Site 310 | Miami | Florida | 33136 | — |
| Viking Clinical Site 221 | Miami Lakes | Florida | 33016 | — |
| Viking Clinical Site 131 | Pensacola | Florida | 32503 | — |
| Viking Clinical Site 215 | Port Orange | Florida | 32127 | — |
| Viking Clinical Site 218 | Sarasota | Florida | 34240 | — |
| Viking Clinical Site 144 | Atlanta | Georgia | 30309 | — |
| Viking Clinical Site 111 | Marietta | Georgia | 30060 | — |
| Viking Clinical Site 120 | Indianapolis | Indiana | 46202 | — |
| Viking Clinical Site 130 | South Bend | Indiana | 46635 | — |
| Viking Clinical Site 211 | West Des Moines | Iowa | 50265 | — |
| Viking Clinical Site 145 | Topeka | Kansas | 66606 | — |
| Viking Clinical Site 146 | Marrero | Louisiana | 70072 | — |
| Viking Clinical Site 307 | New Orleans | Louisiana | 70112 | — |
| Viking Clinical Site 166 | West Monroe | Louisiana | 71291 | — |
| Viking Clinical Site 109 | Baltimore | Maryland | 21202 | — |
| Viking Clinical Site 107 | Greenbelt | Maryland | 20770 | — |
| Viking Clinical Site 147 | Boston | Massachusetts | 02111 | — |
| Viking Clinical Site 158 | Ann Arbor | Michigan | 48109 | — |
| Viking Clinical Site 133 | Detroit | Michigan | 48202 | — |
| Viking Clinical Site 213 | Jackson | Mississippi | 39216 | — |
| Viking Clinical Site 112 | Kansas City | Missouri | 64111 | — |
| Viking Clinical Site 217 | Kansas City | Missouri | 64131 | — |
| Viking Clinical Site 160 | Las Vegas | Nevada | 89106 | — |
| Viking Clinical Site 223 | Reno | Nevada | 89511 | — |
| Viking Clinical Site 152 | New York | New York | 10033 | — |
| Viking Clinical Site 128 | Rochester | New York | 14642 | — |
| Viking Clinical Site 314 | Chapel Hill | North Carolina | 27514 | — |
| Viking Clinical Site 126 | Concord | North Carolina | 28027 | — |
| Viking Clinical Site 116 | Durham | North Carolina | 27710 | — |
| Viking Clinical Site 153 | Morehead City | North Carolina | 28557 | — |
| Viking Clinical Site 137 | Cincinnati | Ohio | 45249 | — |
| Viking Clinical Site 148 | Philadelphia | Pennsylvania | 19107 | — |
| Viking Clinical Site 311 | Pittsburgh | Pennsylvania | 15213 | — |
| Viking Clinical Site 127 | Greenville | South Carolina | 29605 | — |
| Viking Clinical Site 227 | Clarksville | Tennessee | 37040 | — |
| Viking Clinical Site 118 | Hermitage | Tennessee | 37076 | — |
| Viking Clinical Site 115 | Arlington | Texas | 76012 | — |
| Viking Clinical Site 113 | Dallas | Texas | 75203 | — |
| Viking Clinical Site 220 | Edinburg | Texas | 78539 | — |
| Viking Clinical Site 142 | Houston | Texas | 77030 | — |
| Viking Clinical Site 102 | San Antonio | Texas | 78215 | — |
| Viking Clinical Site 101 | San Antonio | Texas | 78229 | — |
| Viking Clinical Site 143 | San Antonio | Texas | 78229 | — |
| Viking Clinical Site 201 | San Antonio | Texas | 78229 | — |
| Viking Clinical Site 224 | Ogden | Utah | 84405 | — |
| Viking Clinical Site 304 | Newport News | Virginia | 23602 | — |
| Viking Clinical Site 209 | Richmond | Virginia | 23249 | — |
| Viking Clinical Site 312 | Richmond | Virginia | 23298 | — |
| Viking Clinical Site 317 | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
Recently updated NASH - Nonalcoholic Steatohepatitis trials
Other public records listing NASH - Nonalcoholic Steatohepatitis. Sorted by last update posted; newest first. Not a recommendation.
- NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects Active, not recruiting
- NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) Active, not recruiting
- NCT04054310: Non-Invasive Quantification of Liver Health in NASH (N-QUAN) Recruiting
- NCT03900429: A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis Active, not recruiting
- NCT03587831: Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis Recruiting
- NCT05165446: Novel MRE Technique to Assess a Risk Factor for Liver Cancer Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04173065, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 13, 2024 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04173065 live on ClinicalTrials.gov.